Cellectar Biosciences

Historical price data

Cellectar Biosciences is a clinical-stage oncology company leveraging its proprietary Phospholipid Drug Conjugate (PDC) platform to develop targeted therapeutics for cancer. Its lead asset, iopofosine I 131, is in late-stage development for relapsed/refractory multiple myeloma and other hematologic malignancies, representing a potential first-in-class targeted radiotherapeutic. The company's strategy is to exploit the unique lipid metabolism of cancer cells to deliver diverse payloads with precision, thereby improving therapeutic indices. Despite its innovative platform, Cellectar operates with a micro-cap valuation, reflecting the high-risk, binary nature of its late-stage clinical programs.

Proprietary Phospholipid Drug Conjugate (PDC) platform that exploits increased lipid raft content in cancer cell membranes to selectively deliver therapeutic payloads (radioisotopes, cytotoxins, biologics) directly to tumors.

Iopofosine competes in a crowded RRMM space against biologics, bispecifics, and CAR-T therapies, requiring clear differentiation. As a platform, PDC technology competes with established modalities like Antibody-Drug Conjugates (ADCs), claiming advantages in tumor penetration due to smaller size and a unique lipid-raft targeting mechanism.